{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:49:15Z","timestamp":1773384555417,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA013035"],"award-info":[{"award-number":["UG1DA013035"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA0135831"],"award-info":[{"award-number":["UG1DA0135831"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Opioid use disorder continues to be a significant problem in the United States and worldwide. Three medications\u2014methadone, buprenorphine, and extended-release injectable naltrexone,\u2014 are efficacious for treating opioid use disorder (OUD). However, the utility of these medications is limited, in part due to poor rates of retention in treatment. In addition, minimum recovery milestones and other factors that influence when and whether individuals can safely discontinue medications are unknown. The National Drug Abuse Treatment Clinical Trials Network (CTN) study \u201cOptimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy\u201d (RDD; CTN-0100) will be among the largest clinical trials on treatment of OUD yet conducted, consisting of two phases, the Retention phase, and the Duration-Discontinuation phase. The Retention phase, open to patients initiating treatment, will test different doses and formulations of buprenorphine (standard dose sublingual, high dose sublingual, or extended-release injection), and a digital therapeutic app delivering contingency management and cognitive behavioral counseling on the primary outcome of retention in treatment. The Discontinuation phase, open to patients in stable remission from OUD and choosing to discontinue medication (including participants from the Retention phase or from the population of patients treated at the clinical site, referred by an outside prescriber or self-referred) will study different tapering strategies for buprenorphine (sublingual taper vs taper with injection buprenorphine), and a digital therapeutic app which provides resources to promote recovery, on the primary outcome of relapse-free discontinuation of medication. This paper describes how the RDD trial derives from two decades of research in the CTN. Initial trials (CTN-0001; CTN-0002; CTN-0003) focused on opioid detoxification, showing buprenorphine-naloxone was effective for detoxification, but that acute detoxification did not appear to be an effective treatment strategy. Trials on comparative effectiveness of medications for opioid use disorder (MOUD) (CTN-0027; CTN-0030; and CTN-0051) highlighted the problem of dropout from treatment and few trials defined retention on MOUD as the primary outcome. Long-term follow-up studies on those patient samples demonstrated the importance of long-term continuation of medication for many patients to sustain remission. Overall, these trials highlight the potential of a stable research infrastructure such as CTN to advance treatment effectiveness through a programmatic succession of large clinical trials.<\/jats:p>","DOI":"10.1186\/s13722-021-00223-z","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T12:03:08Z","timestamp":1615032188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 \u201coptimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)\u201d"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2941-8895","authenticated-orcid":false,"given":"Matisyahu","family":"Shulman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Novo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Costello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,6]]},"reference":[{"issue":"2","key":"223_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","volume":"76","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry. 2019;76(2):208\u201316.","journal-title":"JAMA Psychiatry."},{"key":"223_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1749-6632.2000.tb06683.x","volume":"909","author":"MJ Kreek","year":"2000","unstructured":"Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186\u2013216.","journal-title":"Ann N Y Acad Sci."},{"key":"223_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1749-6632.2011.06352.x","volume":"1248","author":"ND Campbell","year":"2012","unstructured":"Campbell ND, Lovell AM. The history of the development of buprenorphine as an addiction therapeutic. Ann N Y Acad Sci. 2012;1248:124\u201339.","journal-title":"Ann N Y Acad Sci"},{"issue":"10173","key":"223_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","volume":"393","author":"BR Haight","year":"2019","unstructured":"Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2019;393(10173):778\u201390.","journal-title":"Lancet Lond Engl"},{"issue":"8","key":"223_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/adaw.32270","volume":"31","author":"A Knopf","year":"2019","unstructured":"Knopf A. Sublocade trial data published: better than placebo. Alcohol Drug Abuse Wkly. 2019;31(8):4\u20134.","journal-title":"Alcohol Drug Abuse Wkly"},{"key":"223_CR6","unstructured":"Tiberg F. US FDA issues a tentative approval of BrixadiTM (buprenorphine) extended-release injection for treatment of opioid use disorder. Camurus; 2018. https:\/\/mb.cision.com\/Main\/13456\/2715933\/975197.pdf"},{"issue":"1","key":"223_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0741-8329(95)02038-1","volume":"13","author":"CP O\u2019Brien","year":"1996","unstructured":"O\u2019Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol Fayettev N. 1996;13(1):35\u20139.","journal-title":"Alcohol Fayettev N"},{"key":"223_CR8","unstructured":"Overdose Death Rates. NIDA. 2020. https:\/\/www.drugabuse.gov\/related-topics\/trends-statistics\/overdose-death-rates"},{"key":"223_CR9","unstructured":"NIDA. NIDA\u2019s Clinical Trials Network Marks Progress Toward Improved Drug Abuse Treatment. 2002; https:\/\/archives.drugabuse.gov\/news-events\/nida-notes\/2002\/02\/nidas-clinical-trials-network-marks-progress-toward-improved-drug-abuse-treatment"},{"key":"223_CR10","unstructured":"National Institute on Drug Abuse. Center for Clinical Trials Network (CCTN). DrugAbuse.gov. 2011. https:\/\/www.drugabuse.gov\/about-nida\/organization\/center-clinical-trials-network-cctn"},{"issue":"6","key":"223_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0740-5472(97)00016-0","volume":"14","author":"Y-I Hser","year":"1997","unstructured":"Hser Y-I, Anglin MD, Grella C, Longshore D, Prendergast ML. Drug treatment careers A conceptual framework and existing research findings. J Subst Abuse Treat. 1997;14(6):543\u201358.","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"223_CR12","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/j.1360-0443.2005.01154.x","volume":"100","author":"W Ling","year":"2005","unstructured":"Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addict Abingdon Engl. 2005;100(8):1090\u2013100.","journal-title":"Addict Abingdon Engl"},{"issue":"2","key":"223_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1360-0443.2008.02455.x","volume":"104","author":"W Ling","year":"2009","unstructured":"Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, et al. Buprenorphine tapering schedule and illicit opioid use. Addict Abingdon Engl. 2009;104(2):256\u201365.","journal-title":"Addict Abingdon Engl"},{"issue":"17","key":"223_CR14","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2008.574","volume":"300","author":"GE Woody","year":"2008","unstructured":"Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003\u201311.","journal-title":"JAMA"},{"issue":"12","key":"223_CR15","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","volume":"68","author":"RD Weiss","year":"2011","unstructured":"Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238\u201346.","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20132","key":"223_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","volume":"128","author":"AJ Saxon","year":"2013","unstructured":"Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, et al. Buprenorphine\/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013;128(1\u20132):71\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"223_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"Y-I Hser","year":"2014","unstructured":"Hser Y-I, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addict Abingdon Engl. 2014;109(1):79\u201387.","journal-title":"Addict Abingdon Engl"},{"issue":"10118","key":"223_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","volume":"391","author":"JD Lee","year":"2018","unstructured":"Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet Lond Engl. 2018;391(10118):309\u201318.","journal-title":"Lancet Lond Engl."},{"issue":"6","key":"223_CR19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1176\/appi.ajp.2014.13081055","volume":"171","author":"ANC Campbell","year":"2014","unstructured":"Campbell ANC, Nunes EV, Matthews AG, Stitzer M, Miele GM, Polsky D, et al. Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry. 2014;171(6):683\u201390.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"223_CR20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1037\/1064-1297.16.2.132","volume":"16","author":"WK Bickel","year":"2008","unstructured":"Bickel WK, Marsch LA, Buchhalter AR, Badger GJ. Computerized behavior therapy for opioid-dependent outpatients: a randomized controlled trial. Exp Clin Psychopharmacol. 2008;16(2):132\u201343.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"6","key":"223_CR21","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1037\/a0037496","volume":"82","author":"DR Christensen","year":"2014","unstructured":"Christensen DR, Landes RD, Jackson L, Marsch LA, Mancino MJ, Chopra MP, et al. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964\u201372.","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"223_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jsat.2013.08.012","volume":"46","author":"LA Marsch","year":"2014","unstructured":"Marsch LA, Guarino H, Acosta M, Aponte-Melendez Y, Cleland C, Grabinski M, et al. Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment. J Subst Abuse Treat. 2014;46(1):43\u201351.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"223_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/add.13238","volume":"111","author":"Y-I Hser","year":"2016","unstructured":"Hser Y-I, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, et al. Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial. Addict Abingdon Engl. 2016;111(4):695\u2013705.","journal-title":"Addict Abingdon Engl"},{"issue":"150","key":"223_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","volume":"1","author":"RD Weiss","year":"2015","unstructured":"Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM, McDermott KA, et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend. 2015;1(150):112\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"160","key":"223_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","volume":"1","author":"BJH Yarborough","year":"2016","unstructured":"Yarborough BJH, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend. 2016;1(160):112\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"223_CR26","unstructured":"Greiner M. Medication Status, Opioid Abstinence, and Relapse Following the X:BOT Trial. Oral Presentation presented at: CPDD Annual Meeting; 2020; College on Problems of Drug Dependence."},{"issue":"8","key":"223_CR27","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","volume":"174","author":"JM Liebschutz","year":"2014","unstructured":"Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1369\u201376.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"223_CR28","doi-asserted-by":"publisher","first-page":"74.e11","DOI":"10.1016\/j.amjmed.2012.07.005","volume":"126","author":"DA Fiellin","year":"2013","unstructured":"Fiellin DA, Barry DT, Sullivan LE, Cutter CJ, Moore BA, O\u2019Connor PG, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126(1):74.e11-17.","journal-title":"Am J Med"},{"issue":"1","key":"223_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22\u201335.","journal-title":"J Addict Dis"},{"issue":"176","key":"223_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.drugalcdep.2017.03.013","volume":"01","author":"B Eastwood","year":"2017","unstructured":"Eastwood B, Strang J, Marsden J. Effectiveness of treatment for opioid use disorder: a national, five-year, prospective, observational study in England. Drug Alcohol Depend. 2017;01(176):139\u201347.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"223_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","volume":"177","author":"AR Williams","year":"2020","unstructured":"Williams AR, Samples H, Crystal S, Olfson M. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. Am J Psychiatry. 2020;177(2):117\u201324.","journal-title":"Am J Psychiatry"},{"key":"223_CR32","unstructured":"Gustafson DH, Bosworth K, Hawkins RP, Boberg EW, Bricker E. CHESS: a computer-based system for providing information, referrals, decision support and social support to people facing medical and other health-related crises. Proc Symp Comput Appl Med Care. 1992. pp. 161\u20135."},{"issue":"3","key":"223_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1386-5056(02)00048-5","volume":"65","author":"DH Gustafson","year":"2002","unstructured":"Gustafson DH, Hawkins RP, Boberg EW, McTavish F, Owens B, Wise M, et al. CHESS: 10 years of research and development in consumer health informatics for broad populations, including the underserved. Int J Med Inf. 2002;65(3):169\u201377.","journal-title":"Int J Med Inf"},{"issue":"1","key":"223_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00952990.2018.1546862","volume":"45","author":"AR Williams","year":"2019","unstructured":"Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M. Development of a Cascade of Care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45(1):1\u201310.","journal-title":"Am J Drug Alcohol Abuse"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-021-00223-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13722-021-00223-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-021-00223-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T12:18:24Z","timestamp":1615033104000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-021-00223-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,6]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["223"],"URL":"https:\/\/doi.org\/10.1186\/s13722-021-00223-z","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,6]]},"assertion":[{"value":"22 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for the RDD study has been obtained through the BRANY institutional review board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EVN served as unpaid consultant to Alkermes, Braeburn-Camurus and Pear Therapeutics and has received in-kind medication for studies from Reckitt\/Indivior, Alkermes, and a therapeutic application from Pear Therapeutics for a study. RW has consulted to Takeda Pharmaceuticals, Analgesic Solutions, Astellas Pharma, and Cerevel Therapeutics. JR reports medication for the present study from Indivior and Braeburn, and medication and\/or funds for other studies (as principal investigator or investigator) from Indivior and Alkermes. MS, PN, EC all have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}